Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women

References

• Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause 1999; 6: 273–276
   PubMed Web of Science ®Google Scholar
• Lobo R A, Whitehead M I. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable?. Climacteric 2001; 4: 110–119
   PubMedGoogle Scholar
• Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Anderson G L, Limacher M, Assaf A R, Bassford T, Beresford S A, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 2003; 10: 6–12
   PubMed Web of Science ®Google Scholar
• Lobo R A, Ettinger B, Hutchinson K A, Knopp R H, Lindsay R, Nachtigall L E, Santoro N, Studd J. Estrogen replacement. The evolving role of transdermal delivery. J Reprod Med 1996; 41: 781–796
   PubMedGoogle Scholar
• Montgomery R V. Hormone replacement therapy: optimising the dose and route of administration. Drugs Aging 2002; 19: 807–818
   PubMedGoogle Scholar
• Doren M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum Reprod Update 2000; 6: 419–426
   PubMedGoogle Scholar
• Garnero P, Delmas P D. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004; 4: 50–63
   PubMedGoogle Scholar
• Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005; 27: 1–11
   PubMed Web of Science ®Google Scholar
• Garcia-Perez M A, Moreno-Mercer J, Tarin J J, Cano A. Relationship between PTH, sex steroid and bone turnover marker measurements and bone density in recently postmenopausal women. Maturitas 2003; 45: 67–74
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Claustrat B, Delmas P D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526–1536
   PubMed Web of Science ®Google Scholar
• Ross P D, Kress B C, Parson R E, Wasnich R D, Armour K A, Mizrahi I A. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000; 11: 76–82
   PubMed Web of Science ®Google Scholar
• Garnero P, Bianchi F, Carlier M C, Genty V, Jacob N, Kamel S, Kindermans C, Plouvier E, Pressac M, Souberbielle J C. [Biochemical markers of bone remodeling: pre-analytical variations and guidelines for their use. SFBC (Societe Francaise de Biologie Clinique) Work Group. Biochemical markers of bone remodeling]. Ann Biol Clin (Paris) 2000; 58: 683–704
   PubMed Web of Science ®Google Scholar
• Woitge H W, Scheidt-Nave C, Kissling C, Leidig-Bruckner G, Meyer K, Grauer A, Scharla S H, Ziegler R, Seibel M J. Seasonal variation of biochemical indexes of bone turnover: results of a population-based study. J Clin Endocrinol Metab 1998; 83: 68–75
   PubMed Web of Science ®Google Scholar
• Riggs B L, Melton L J, III. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002; 17: 11–14
   PubMed Web of Science ®Google Scholar
• Heshmati H M, Khosla S, Robins S P, O'Fallon W M, Melton L J, III, Riggs B L. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002; 17: 172–178
   PubMed Web of Science ®Google Scholar
• Rubinacci A, Peruzzi E, Modena A B, Zanardi E, Andrei B, De Leo V, Pansini F S, Quebe-Fehling E, de Palacios P I. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. Menopause 2003; 10: 241–249
   PubMed Web of Science ®Google Scholar
• Cooper C, Stakkestad J A, Radowicki S, Hardy P, Pilate C, Dain M P, Delmas P D. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporos Int 1999; 9: 358–366
   PubMed Web of Science ®Google Scholar
• Weiss S R, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol 1999; 94: 330–336
   PubMedGoogle Scholar
• Lindsay R, Hart D M, Purdie D, Ferguson M M, Clark A S, Kraszewski A. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med 1978; 54: 193–195
   PubMedGoogle Scholar
• Miles R A, Paulson R J, Lobo R A, Press M F, Dahmoush L, Sauer M V. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994; 62: 485–490
   PubMed Web of Science ®Google Scholar
• Utian W H, Burry K A, Archer D F, Gallagher J C, Boyett R L, Guy M P, Tachon G J, Chadha-Boreham H K, Bouvet A A. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol 1999; 181: 71–79
   PubMed Web of Science ®Google Scholar
• Minisola S, Pacitti M T, Ombricolo E, Costa G, Scarda A, Palombo E, Rosso R. Bone turnover and its relationship with bone mineral density in pre- and postmenopausal women with or without fractures. Maturitas 1998; 29: 265–270
   PubMedGoogle Scholar
• Weaver C M, Peacock M, Martin B R, McCabe G P, Zhao J, Smith D L, Wastney M E. Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females. J Bone Miner Res 1997; 12: 1714–1720
   PubMed Web of Science ®Google Scholar
• Takahashi M, Kushida K, Hoshino H, Miura M, Ohishi T, Inoue T. Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis. Clin Endocrinol (Oxf) 1997; 47: 177–183
   PubMedGoogle Scholar
• Bjarnason N H, Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 2000; 26: 561–569
   PubMed Web of Science ®Google Scholar